Lin B, Nair S, Fellner D, Nasef N, Singh H, Negron L
Foods. 2023; 12(22).
PMID: 38002130
PMC: 10670905.
DOI: 10.3390/foods12224072.
Rashid Z, Bardaweel S
Int J Mol Sci. 2023; 24(15).
PMID: 37569509
PMC: 10418771.
DOI: 10.3390/ijms241512133.
Almutairi S, Kalloush H, Manoon N, Bardaweel S
Molecules. 2023; 28(14).
PMID: 37513440
PMC: 10384300.
DOI: 10.3390/molecules28145567.
Flieger S, Takagaki M, Kondo N, Lutz Jr M, Gupta Y, Ueda H
Int J Mol Sci. 2023; 24(8).
PMID: 37108137
PMC: 10139035.
DOI: 10.3390/ijms24086973.
Beck-Sickinger A, Becker D, Chepurna O, Das B, Flieger S, Hey-Hawkins E
Cancer Biother Radiopharm. 2022; 38(3):160-172.
PMID: 36350709
PMC: 10325817.
DOI: 10.1089/cbr.2022.0060.
Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
Gimeno A, Cuffaro D, Nuti E, Ojeda-Montes M, Beltran-Debon R, Mulero M
Molecules. 2021; 26(15).
PMID: 34361703
PMC: 8347235.
DOI: 10.3390/molecules26154553.
Recent insights into natural product inhibitors of matrix metalloproteinases.
Kumar G, Nair B, Perry J, Martin D
Medchemcomm. 2020; 10(12):2024-2037.
PMID: 32904148
PMC: 7451072.
DOI: 10.1039/c9md00165d.
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.
Fields G
Cells. 2019; 8(9).
PMID: 31461880
PMC: 6769477.
DOI: 10.3390/cells8090984.
Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
Fields G
Front Immunol. 2019; 10:1278.
PMID: 31214203
PMC: 6558196.
DOI: 10.3389/fimmu.2019.01278.
Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.
Naphade S, Embusch A, Lakshika Madushani K, Ring K, Ellerby L
Front Neurosci. 2018; 11:736.
PMID: 29459817
PMC: 5807396.
DOI: 10.3389/fnins.2017.00736.
Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.
Nuti E, Rosalia L, Cuffaro D, Camodeca C, Giacomelli C, Da Pozzo E
ACS Med Chem Lett. 2017; 8(3):293-298.
PMID: 28337319
PMC: 5346986.
DOI: 10.1021/acsmedchemlett.6b00446.
Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.
Winer A, Janosky M, Harrison B, Zhong J, Moussai D, Siyah P
Mol Cancer Ther. 2016; 15(10):2370-2377.
PMID: 27466357
PMC: 5050118.
DOI: 10.1158/1535-7163.MCT-16-0194.
Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues.
Bhowmick M, Stawikowska R, Tokmina-Roszyk D, Fields G
Chembiochem. 2015; 16(7):1084-92.
PMID: 25766890
PMC: 4415627.
DOI: 10.1002/cbic.201402716.
New strategies for targeting matrix metalloproteinases.
Fields G
Matrix Biol. 2015; 44-46:239-46.
PMID: 25595836
PMC: 4466128.
DOI: 10.1016/j.matbio.2015.01.002.
Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.
Pahwa S, Stawikowski M, Fields G
Cancers (Basel). 2014; 6(1):416-35.
PMID: 24549119
PMC: 3980612.
DOI: 10.3390/cancers6010416.
Large-scale transcriptome sequencing and gene analyses in the crab-eating macaque (Macaca fascicularis) for biomedical research.
Huh J, Kim Y, Park S, Kim D, Lee S, Kim K
BMC Genomics. 2012; 13:163.
PMID: 22554259
PMC: 3496626.
DOI: 10.1186/1471-2164-13-163.
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P
Bioorg Med Chem Lett. 2011; 21(23):7180-4.
PMID: 22018790
PMC: 3210410.
DOI: 10.1016/j.bmcl.2011.09.077.
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.
Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E
Eur J Med Chem. 2011; 46(7):2617-29.
PMID: 21514700
PMC: 3319704.
DOI: 10.1016/j.ejmech.2011.03.033.
Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.
Zhang H, Chang M, Hansen C, Basso D, Noble-Haeusslein L
Neurotherapeutics. 2011; 8(2):206-20.
PMID: 21455784
PMC: 3077748.
DOI: 10.1007/s13311-011-0038-0.